BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens

Diagnostic Microbiology and Infectious Disease

Volumn 32, Issue 1, 1998, Pages 45-50

  Biedenbach, Douglas J ^a   Barrett, Mary S ^a   Croco, Matthew A T ^a   Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CEFADROXIL; CEFPODOXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; NEW DRUG; OFLOXACIN; SPARFLOXACIN; TETRACYCLINE; TROVAFLOXACIN; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BETA-LACTAMASES; FLUOROQUINOLONES; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; QUINOLINES; RESPIRATORY TRACT INFECTIONS; SENSITIVITY AND SPECIFICITY; SPECIES SPECIFICITY;

EID: 0032427640     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00042-X     Document Type: Article

References (16)

1. Bauernfeind A (1997) Comparison of the antibacterial activities of the quinolones Bay 12-8039, garifloxacin (AM-1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 40:639-651.
2. Boswell FJ, Andres JM, Wise R (1997) Pharmacodynamic properties of BAY 12-8039 on gram-positive and gramnegative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect. Antimicrob Agents Chemother 41:1377-1379.
3. Brueggemann AB, Kugler KC, Doern GV (1997) In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 41: 1594-1597.
4. Pass RJ (1997) In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother 41: 1818-1824.
5. Georgopoulos A, Buxbaum A, Graininger W (1996) Activity of BAY 12-8039 against 1154 clinical isolates of Streptococcus pneumoniae (abstr F5). Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC.
6. Goldstein EJC, Citron DM, Hudspeth M, Gerardo SH, Merriam CV (1997) In vitro activity of BAY 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans. Antimicrob Agents Chemother 41:1552-1557.
7. Jones RN, Pfaller MA, Doern GV, Verhoef J, Jones ME, Sader HS, SENTRY Study Group (1997) Initial report of a longitudinal, international antimicrobial surveillance study (SENTRY): Alarming resistance rates in monitored sites (68 medical centers) in the USA, Canada, South America, and Europe (abstr E-109). Proceedings of the 37th ICAAC. Toronto, Ontario, Canada.
8. Kayser FH, Santanam P, Huf E (1997) Susceptibilities of invasive pneumococcal strains against the methoxyquinolone BAY 12-8039 compared to other quinolones (abstr. F130). Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada.
9. Kitzis MD, Goldstein FW, Miegi M, Acar JF (1996) In vitro activity of BAY 12-8039 against multiply-resistant Staphylococcus aureus, Streptococcus pneumoniae and Enterococcus faecalis (abstr F12). Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC.
10. National Committee for Clinical Laboratory Standards (NCCLS) (1997) Standard Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard M7-A4. Wayne, PA: NCCLS.
11. National Committee for Clinical Laboratory Standards (NCCLS) (1998) Performance Standards for Antimicrobial Susceptibility Testing: Sixth Information Supplement M100-S8. Wayne, PA: NCCLS.
12. Robson HG, Tremblay J-F, Loo VG, Lavallee J, McAlear D (1997) Comparative in vitro activity of trovafloxacin, BAY 12-8039, and clinafloxacin against penicillin-intermediate and -resistant Streptococcus pneumoniae (abstr F135). Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada.
13. Rouse MS, Piper KE, Patel R, Wilson WR, Steckelberg JM (1997) In vitro and in vivo activity of ciprofloxacin, levofloxacin, sparfloxacin, or BAY 12-8039 against penicillin-resistant Streptococcus pneumoniae (abstr B3). Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada.
14. Souli M, Wennersten CB, Eliopoulos GM (1997) In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, against species representative of respiratory tract pathogens (abstr F126). Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada.
15. Visalli MA, Jacobs MR, Appelbaum PC (1997) Antipneumococcal activity of Bay 12-8039, a new quinolone, compared with activities of three other quinolones and four oral β-lactams. Antimicrob Agents Chemother 41:2786-2789.
16. Woodcock JM, Andres JM, Boswell FJ, Brenwald NP, Wise R (1997) In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 41:101-106.